Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGN786
- Development stage
- Preclinical
- Lead developer
- Igenica Biotherapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IGN786 is an antibody-drug conjugate (ADC) developed by Igenica Biotherapeutics using their proprietary SNAP ADC technology and sTAg proteomics platform for target discovery. It targets SAIL (Surface Antigen In Leukemia, also known as c16orf54 or c15orf54), a novel cell surface protein highly expressed in hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and multiple myeloma, as well as solid tumors like pancreatic cancer, with limited expression in normal tissues. Preclinical studies demonstrate potent tumor regression in AML xenograft models, selective targeting of SAIL-expressing tumors, and a favorable toxicology profile (NOAEL of 20 mg/kg in non-human primates). IGN786 entered a strategic collaboration with MedImmune (AstraZeneca) in 2015-2017, where Igenica provided anti-SAIL antibodies and SNAP linker, and MedImmune contributed payloads for joint preclinical investigation, with MedImmune holding an option for exclusive licensing.[1][2][3][5][11]
- Other names
- anti-SAIL ADC
Beyond the preview
Go deeper on IGN786.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGN786.